Passage Bio报告了upliFT-D的中期数据，显示FTD-GRN中持续的CSF PGRN升高和血浆NfL降低与自然史

2025-06-23 19:07

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history
Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range
Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression
Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026